Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
ARDX Ardelyx
- 5.7900
- +0.1300+2.30%
Close Feb 14 16:00 ET
- 5.7622
- -0.0278-0.48%
Post 19:27 ET
1.37BMarket Cap-18.09P/E (TTM)
5.8850High5.6400Low3.52MVolume5.7200Open5.6600Pre Close20.21MTurnover1.52%Turnover RatioLossP/E (Static)236.85MShares9.830052wk High8.67P/B1.34BFloat Cap4.320052wk Low--Dividend TTM230.78MShs Float35.4800Historical High--Div YieldTTM4.33%Amplitude0.4902Historical Low5.7490Avg Price1Lot Size
About Ardelyx Company
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Company Profile
SymbolARDX
Company NameArdelyx
Listing DateJun 19, 2014
Issue Price14.00
Founded2007
CEOMr. Michael G. Raab
MarketNASDAQ
Employees267
Fiscal Year Ends12-31
Address400 Fifth Avenue,Suite 210
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-510-745-1700
Websitehttp://www.ardelyx.com
Company Executives
- Name
- Position
- Salary
- Michael G. Raab
- Director, President and Chief Executive Officer
- 4.12M
- Robert Blanks
- Chief Regulatory Affairs and Quality Assurance Officer
- --
- David P. Rosenbaum
- Chief Development Officer
- --
- Elizabeth Grammer
- Chief Legal and Administrative Officer
- 1.63M
- Susan Rodriguez
- Chief Commercial Officer
- --
- Justin A. Renz
- Chief Financial and Operations Officer
- --
- Dr. Laura Willia M.D.
- Chief Medical Officer
- 1.63M
- Joseph Reilly
- Principal Accounting Officer
- --
- Mike Kelliher
- Executive Vice President, Corporate Development and Strategy
- --
- David M. Mott
- Chairman of the Board
- 249.90K
- Robert B. Bazemore, Jr
- Independent Director
- 202.40K
- Dr. Jan M. Lundberg, PhD
- Independent Director
- 199.90K
- William C. Bertrand, Esq.,Jr
- Independent Director
- 214.90K
- Muna Bhanji, Ph.
- Independent Director
- 202.40K
- Richard J. Rodgers
- Independent Director
- 222.40K
- Onaiza Cadoret-Manier
- Independent Director
- 199.90K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.